BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36897522)

  • 1. Healthcare Service Use Patterns Among Patients with Acid Sphingomyelinase Deficiency Type B: A Retrospective US Claims Analysis.
    Pulikottil-Jacob R; Ganz ML; Fournier M; Petruski-Ivleva N
    Adv Ther; 2023 May; 40(5):2234-2248. PubMed ID: 36897522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olipudase Alfa in Non-CNS Manifestations of Acid Sphingomyelinase Deficiency: A Profile of Its Use.
    Syed YY
    Clin Drug Investig; 2023 May; 43(5):369-377. PubMed ID: 37133675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-life impacts of olipudase alfa: The experience of patients and families taking an enzyme replacement therapy for acid sphingomyelinase deficiency.
    Raebel EM; Wiseman S; Donnelly C; Mathieson T; Pountney J; Crowe J; Hopkin J
    Orphanet J Rare Dis; 2024 Feb; 19(1):36. PubMed ID: 38303068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cause of death in patients with chronic visceral and chronic neurovisceral acid sphingomyelinase deficiency (Niemann-Pick disease type B and B variant): Literature review and report of new cases.
    Cassiman D; Packman S; Bembi B; Turkia HB; Al-Sayed M; Schiff M; Imrie J; Mabe P; Takahashi T; Mengel KE; Giugliani R; Cox GF
    Mol Genet Metab; 2016 Jul; 118(3):206-213. PubMed ID: 27198631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective study of morbidity and mortality of chronic acid sphingomyelinase deficiency in Germany.
    Mengel E; Muschol N; Weinhold N; Ziagaki A; Neugebauer J; Antoni B; Langer L; Gasparic M; Guillonneau S; Fournier M; Laredo F; Pulikottil-Jacob R
    Orphanet J Rare Dis; 2024 Apr; 19(1):161. PubMed ID: 38615062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continued improvement in disease manifestations of acid sphingomyelinase deficiency for adults with up to 2 years of olipudase alfa treatment: open-label extension of the ASCEND trial.
    Wasserstein MP; Lachmann R; Hollak C; Barbato A; Gallagher RC; Giugliani R; Guelbert NB; Hennermann JB; Ikezoe T; Lidove O; Mabe P; Mengel E; Scarpa M; Senates E; Tchan M; Villarrubia J; Thurberg BL; Yarramaneni A; Armstrong NM; Kim Y; Kumar M
    Orphanet J Rare Dis; 2023 Dec; 18(1):378. PubMed ID: 38042851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olipudase alfa enzyme replacement therapy for acid sphingomyelinase deficiency (ASMD): sustained improvements in clinical outcomes after 6.5 years of treatment in adults.
    Lachmann RH; Diaz GA; Wasserstein MP; Armstrong NM; Yarramaneni A; Kim Y; Kumar M
    Orphanet J Rare Dis; 2023 Apr; 18(1):94. PubMed ID: 37098529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olipudase Alfa: First Approval.
    Keam SJ
    Drugs; 2022 Jun; 82(8):941-947. PubMed ID: 35639287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful within-patient dose escalation of olipudase alfa in acid sphingomyelinase deficiency.
    Wasserstein MP; Jones SA; Soran H; Diaz GA; Lippa N; Thurberg BL; Culm-Merdek K; Shamiyeh E; Inguilizian H; Cox GF; Puga AC
    Mol Genet Metab; 2015; 116(1-2):88-97. PubMed ID: 26049896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact and burden of acid sphingomyelinase deficiency from a patient and caregiver perspective.
    Pokrzywinski R; Hareendran A; Nalysnyk L; Cowie S; Crowe J; Hopkin J; Joshi D; Pulikottil-Jacob R
    Sci Rep; 2021 Oct; 11(1):20972. PubMed ID: 34697402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommendations for clinical monitoring of patients with acid sphingomyelinase deficiency (ASMD).
    Wasserstein M; Dionisi-Vici C; Giugliani R; Hwu WL; Lidove O; Lukacs Z; Mengel E; Mistry PK; Schuchman EH; McGovern M
    Mol Genet Metab; 2019 Feb; 126(2):98-105. PubMed ID: 30514648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival of patients with chronic acid sphingomyelinase deficiency (ASMD) in the United States: A retrospective chart review study.
    Pulikottil-Jacob R; Dehipawala S; Smith B; Athavale A; Gusto G; Chandak A; Khachatryan A; Banon T; Fournier M; Guillonneau S; Pollissard L; Munoz-Rojas MV
    Mol Genet Metab Rep; 2024 Mar; 38():101040. PubMed ID: 38188692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease manifestations and burden of illness in patients with acid sphingomyelinase deficiency (ASMD).
    McGovern MM; Avetisyan R; Sanson BJ; Lidove O
    Orphanet J Rare Dis; 2017 Feb; 12(1):41. PubMed ID: 28228103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olipudase alfa for treatment of acid sphingomyelinase deficiency (ASMD): safety and efficacy in adults treated for 30 months.
    Wasserstein MP; Diaz GA; Lachmann RH; Jouvin MH; Nandy I; Ji AJ; Puga AC
    J Inherit Metab Dis; 2018 Sep; 41(5):829-838. PubMed ID: 29305734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acid Sphingomyelinase Deficiency: Sharing Experience of Disease Monitoring and Severity in France.
    Mauhin W; Borie R; Dalbies F; Douillard C; Guffon N; Lavigne C; Lidove O; Brassier A
    J Clin Med; 2022 Feb; 11(4):. PubMed ID: 35207195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective study of the natural history of chronic acid sphingomyelinase deficiency in children and adults: eleven years of observation.
    McGovern MM; Wasserstein MP; Bembi B; Giugliani R; Mengel KE; Vanier MT; Zhang Q; Peterschmitt MJ
    Orphanet J Rare Dis; 2021 May; 16(1):212. PubMed ID: 33971920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, placebo-controlled clinical trial evaluating olipudase alfa enzyme replacement therapy for chronic acid sphingomyelinase deficiency (ASMD) in adults: One-year results.
    Wasserstein M; Lachmann R; Hollak C; Arash-Kaps L; Barbato A; Gallagher RC; Giugliani R; Guelbert NB; Ikezoe T; Lidove O; Mabe P; Mengel E; Scarpa M; Senates E; Tchan M; Villarrubia J; Chen Y; Furey S; Thurberg BL; Zaher A; Kumar M
    Genet Med; 2022 Jul; 24(7):1425-1436. PubMed ID: 35471153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzyme replacement therapy for children with acid sphingomyelinase deficiency in the real world: A single center experience in Taiwan.
    Pan YW; Tsai MC; Yang CY; Yu WH; Wang B; Yang YJ; Chou YY
    Mol Genet Metab Rep; 2023 Mar; 34():100957. PubMed ID: 36873248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clearance of Hepatic Sphingomyelin by Olipudase Alfa Is Associated With Improvement in Lipid Profiles in Acid Sphingomyelinase Deficiency.
    Thurberg BL; Wasserstein MP; Jones SA; Schiano TD; Cox GF; Puga AC
    Am J Surg Pathol; 2016 Sep; 40(9):1232-42. PubMed ID: 27340749
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.